Overview

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Status:
Terminated

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.

Phase:

Phase 3

Details

Lead Sponsor:

Sarcoma Alliance for Research through Collaboration

Collaborator:

Novartis Pharmaceuticals

Treatments:

Imatinib Mesylate